I am pleased to announce the elevation of the Institute for Infectious and Inflammatory Diseases (I3D) within New Jersey Medical School (NJMS) to a Chancellor level institute at Rutgers Biomedical and Health Sciences. The I3D covers an area of great research excellence at Rutgers Biomedical and Health Sciences (RBHS) and is a signature component of our strategic plan, identified as an area where we can become a national leader.
I3D researchers represent an impressive cross-section of disciplines including pathogenesis, diagnostics, host defense, and inflammation. Inflammatory disorders, contributing to diseases ranging from the common cold to cancer, are caused by harmful immune responses, and proven contributors to a host of life threatening ailments. Our accomplished scientists are aggressively investigating the causes of disease with an emphasis on rapid detection and the development of new therapies to control harmful inflammation and infection. Target diseases include AIDS, tuberculosis, malaria, influenza, fungal and parasitic infections, diabetes, obesity, and Crohn’s disease.
The core of the institute will be comprised of several of our most productive research centers including: the NJMS Public Health Research Institute, led by Dr. David Perlin; the NJMS Ruy Lorenco Center for Emerging and Reemerging Pathogens, led by Dr. David Alland; and the NJMS Center for Immunity and Inflammation, led by Dr. William C. Gause. In addition, individual faculty members from across Rutgers University will participate in activities focused on the research areas within this institute. Dr. Gause will be assuming a leadership role of the I3D, as director.
Please join me in commending the I3D leadership for organizing this area of research strength at RBHS into a strategically-focused, highly competitive, inter-disciplinary research institute with the potential to contribute to scientific innovation, discovery, and patient care on a global scale.
Brian L. Strom, MD, MPH
Chancellor, Rutgers Biomedical and Health Sciences
Executive Vice President for Health Affairs